Kin Yip Leung

Kin Yip Leung

Director/Board Member at NOVOCURE LIMITED

Net worth: 1 M $ as of 2026-02-27

65 year
Health Technology
Consumer Services
Commercial Services

Profile

Kin Yip Leung currently works at NovoCure Ltd., as Vice Chairman from 2011.
Mr. Leung also formerly worked at Curia Global, Inc., as Independent Director from 2010 to 2016, Delcath Systems, Inc., as Director in 2014, NanoMed Pharmaceuticals, Inc., as Director, Pernix Therapeutics Holdings, Inc., as Independent Non-Executive Director from 2016 to 2019, Bristol Myers Squibb Co., as Principal from 1990 to 1999, OSI Pharmaceuticals, Inc., as EVP, President-Oncology & Diabetes Business from 2003 to 2010, Pharmacia Corp., as Group Vice President-Global Prescription Business from 1999 to 2003, and C-Change, as Member.
Mr. Leung received his undergraduate degree from The University of Texas at Austin and graduate degree from the University of Wisconsin.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2025-06-03 92,444 ( 0.08% ) 1 M $ 2026-02-27

Kin Yip Leung active positions

CompaniesPositionStart
NOVOCURE LIMITED Director/Board Member 2011-08-04

Former positions of Kin Yip Leung

CompaniesPositionEnd
PERNIX THERAPEUTICS HOLDINGS INC Director/Board Member 2019-05-08
ALBANY MOLECULAR RESEARCH, INC. Director/Board Member 2016-02-03
DELCATH SYSTEMS, INC. Chairman 2014-09-14
OSI PHARMACEUTICALS, INC. Corporate Officer/Principal 2009-12-31
Corporate Officer/Principal 2003-03-31
See the detail of Kin Yip Leung's experience

Training of Kin Yip Leung

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

76

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW